As part of the deal, arGEN-X has licensed the firm’s POTELLIGENT CHOK1SV Cell Line Technology for use in the development of ARGX-110, a proprietary antibody in its pipeline.
Under the deal, Falk Pharma will assume responsibility and all costs relating to the clinical development and marketing of RhuDex. In return, Medigene will get an upfront payment
Basis of the new vaccine formulation and analysis service are advanced, precise and highly informative analytical techniques. The new service will be centred on XstalBio’s proprietary solid state
The company is focused on the discovery and development of innovative antibodies and antibody-drug conjugates (ADCs) for the treatment of cancer. The trial is designed to evaluate the
Currently, Xtandi is approved for the treatment of patients with mCRPC who have previously received docetaxel chemotherapy. The sNDA is based on the results from the Phase III
In Switzerland, Jetrea will be launched by ThromboGenics’ partner Alcon, a division of Novartis. Jetrea is the first pharmacological treatment for VMT and was approved by the European
Senior Scientific, a division of Manhattan Scientifics, has manufactured nanoparticles primarily to support its NanoMRX cancer detection technology. Now the company is making them available for other applications.
The team at VMBD will use the tool of metabolic engineering to transfer cannabis genetic pathways in microbes representing an alternative route to produce cannabinoids at an affordable
The deal will create new mobile and internet-based services to support patients through their treatment journey, improving medication adherence and giving patients confidence to manage their condition more
Bioasis is focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier. As part of the deal, MedImmune will assess the therapeutic effect of its
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.